Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Rehlinghaus

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Aktuelle Urologie|August 22, 2023
[Neutropenia - when is GCSF support indicated?]Marc Rehlinghaus, Philipp Rehker, Yue Che, et al.
Der Urologe. Ausg. A|January 28, 2022
[Metastatic urothelial carcinoma-guideline-based therapy and new options]Günter Niegisch, Gunhild von Amsberg, Marc Rehlinghaus, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
European Urology Open Science|July 23, 2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS ProjectThomas Hilser, Jozefina Casuscelli, Can Aydogdu, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Aktuelle Urologie|August 22, 2023
[Neutropenia - when is GCSF support indicated?]Marc Rehlinghaus, Philipp Rehker, Yue Che, et al.
Der Urologe. Ausg. A|January 28, 2022
[Metastatic urothelial carcinoma-guideline-based therapy and new options]Günter Niegisch, Gunhild von Amsberg, Marc Rehlinghaus, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
European Urology Open Science|July 23, 2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS ProjectThomas Hilser, Jozefina Casuscelli, Can Aydogdu, et al.
Pageof 1